Viruses 2013, 5(1), 352-373; doi:10.3390/v5010352
Review

Influenza A Virus Entry Inhibitors Targeting the Hemagglutinin

Received: 14 December 2012; in revised form: 17 January 2013 / Accepted: 21 January 2013 / Published: 22 January 2013
(This article belongs to the Special Issue Viral Entry Inhibitors)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: Influenza A virus (IAV) has caused seasonal influenza epidemics and influenza pandemics, which resulted in serious threat to public health and socioeconomic impacts. Until now, only 5 drugs belong to two categories are used for prophylaxis and treatment of IAV infection. Hemagglutinin (HA), the envelope glycoprotein of IAV, plays a critical role in viral binding, fusion and entry. Therefore, HA is an attractive target for developing anti‑IAV drugs to block the entry step of IAV infection. Here we reviewed the recent progress in the study of conformational changes of HA during viral fusion process and the development of HA-based IAV entry inhibitors, which may provide a new choice for controlling future influenza pandemics.
Keywords: influenza A virus; hemagglutinin; viral entry; antiviral drugs
PDF Full-text Download PDF Full-Text [365 KB, uploaded 22 January 2013 11:35 CET]

Export to BibTeX |
EndNote


MDPI and ACS Style

Yang, J.; Li, M.; Shen, X.; Liu, S. Influenza A Virus Entry Inhibitors Targeting the Hemagglutinin. Viruses 2013, 5, 352-373.

AMA Style

Yang J, Li M, Shen X, Liu S. Influenza A Virus Entry Inhibitors Targeting the Hemagglutinin. Viruses. 2013; 5(1):352-373.

Chicago/Turabian Style

Yang, Jie; Li, Minmin; Shen, Xintian; Liu, Shuwen. 2013. "Influenza A Virus Entry Inhibitors Targeting the Hemagglutinin." Viruses 5, no. 1: 352-373.

Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert